BRIEF—China approves first generic of Volibris

China’s medicines regulator has give approval for the drug approval application for the country's first genetic version of UK pharma major GlaxoSmithKline’s Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH).

The Chinese manufacturer is Lianyungang, Jiangsu province-based Hansoh Pharma.

An orphan drug, the compound is also being developed by other 15 Chinese companies, with four of them waiting for their drug approvals, including Chiatai Tianqing and Huahai Pharmaceutical, according to China pharma data service DXY Insight.